CytomX Therapeutics, Inc.

This oncology-focused biopharmaceutical company develops conditionally activated biologics designed to localize therapeutic activity within the tumor microenvironment. The company operates two primary technology platforms: its conditional activation platform, which enhances the therapeutic window for antibodies, antibody-drug conjugates (ADCs), T-cell engagers, and immune modulators in oncology; and its PROBODY platform, which is being explored in both oncology and non-oncology indications. Lead clinical candidates include CX-904, a T-cell-engaging bispecific antibody targeting EGFR and CD3; CX-2051, a conditionally activated ADC for EpCAM-expressing epithelial cancers; and CX-801, an interferon alpha-2b cytokine in clinical development.

The company maintains a development pipeline that includes additional ADCs and PROBODY-engineered therapeutics. Revenue streams consist primarily of milestone payments and research funding from strategic partnerships, with collaborating partners including Amgen, Astellas, Bristol Myers Squibb, Regeneron, and Moderna. The company also maintains a clinical trial collaboration and supply agreement with Merck for CX-801 in combination with anti-PD-1 therapy.

Based in South San Francisco, California, the company operates with a workforce of 119 full-time employees as of the most recent disclosure. CytomX was incorporated in Delaware and founded in 2008.